# Taysha Gene Therapies, Inc. — Form D

Taysha Gene Therapies, Inc. of DALLAS, TX, a company, filed a Form D exempt-offering notice with the SEC on 2020-08-18. The offering totals $96.0M, of which $96.0M was reported sold. Industry: Biotechnology.

## Offering

- Filed: 2020-08-18
- Form: D
- Accession: 0001806310-20-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $96.0M
- Amount sold: $96.0M
- Investors: 26
- Date of first sale: 2020-07-02
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-373497

## Issuer

- Name: Taysha Gene Therapies, Inc.
- CIK: 0001806310
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 3000 PEGASUS PARK DRIVE, DALLAS, TX, 75247
- Phone: (214) 612-0000

## Officers, directors & promoters (24)

| Name | Role | Location |
| --- | --- | --- |
| Sean A Nolan | Director | Dallas, TX |
| R. A Session II | Director | Dallas, TX |
| R. A Session II | Executive Officer | Dallas, TX |
| Paul B Manning | Director | West Chester, PA |
| Sean Nolan | Director | WALTHAM, MA |
| Phillip B Donenberg | Director | Watertown, MA |
| Phillip P Donenberg | Director | Dallas, TX |
| Sean P Nolan | Director | Dallas, TX |
| Sean P Nolan | Executive Officer | Dallas, TX |
| Laura P Sepp-Lorenzino | Director | Dallas, TX |
| Sean P Stalfort | Director | Dallas, TX |
| Kamran P Alam | Executive Officer | Dallas, TX |
| Kathleen P Reape | Director | Dallas, TX |
| Sukumar P Nagendran | Director | Dallas, TX |
| Sukumar P Nagendran | Executive Officer | Dallas, TX |
| Laura B Sepp-Lorenzino | Director | Dallas, TX |
| RA Session II | Director | Dallas, TX |
| RA Session II | Executive Officer | Dallas, TX |
| Kathleen B Reape | Director | Dallas, TX |
| Kamran B Alam | Executive Officer | Dallas, TX |
| Suyash B Prasad | Executive Officer | Dallas, TX |
| Sukumar B Nagendran | Director | Dallas, TX |
| R.A. Session II | Director | Dallas, TX |
| R.A. Session II | Executive Officer | Dallas, TX |

## Other filings by this issuer (3)

| Filed | Form | Offering | Sold |
| --- | --- | --- | --- |
| [2023-08-25](https://search.stillhousedata.com/formd/0001231919-23-000063) | D | $150.0M | $150.0M |
| [2022-11-07](https://search.stillhousedata.com/formd/0001806310-22-000001) | D | $30.0M | $30.0M |
| [2020-05-04](https://search.stillhousedata.com/formd/0001806310-20-000001) | D | $30.0M | $18.0M |

## More

- [CIK 1806310 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1806310&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001806310-20-000002.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.